The global osteoporosis drugs market size reached US$ 16.6 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 24.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.33% during 2023-2032.
Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.
The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide.
Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years.
2. What is the expected growth rate of the global osteoporosis drugs market during 2024-2032?
3. What are the key factors driving the global osteoporosis drugs market?
4. What has been the impact of COVID-19 on the global osteoporosis drugs market?
5. What is the breakup of the global osteoporosis drugs market based on the product type?
6. What is the breakup of the global osteoporosis drugs market based on the route of administration?
7. What are the key regions in the global osteoporosis drugs market?
8. Who are the key players/companies in the global osteoporosis drugs market?
Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.
The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide.
Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global osteoporosis drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type and route of administration.Breakup by Product Type:
- Bisphosphonates
- Calcitonin
- Rank Ligand Inhibitor
- Parathyroid Hormone Therapy (PTH)
- Selective Estrogen Receptor Modulators (SERMs)
- Sclerostin Inhibitor
- Others
Breakup by Route of Administration:
- Oral
- Injectable
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.Key Questions Answered in This Report
1. How big is the global osteoporosis drugs market?2. What is the expected growth rate of the global osteoporosis drugs market during 2024-2032?
3. What are the key factors driving the global osteoporosis drugs market?
4. What has been the impact of COVID-19 on the global osteoporosis drugs market?
5. What is the breakup of the global osteoporosis drugs market based on the product type?
6. What is the breakup of the global osteoporosis drugs market based on the route of administration?
7. What are the key regions in the global osteoporosis drugs market?
8. Who are the key players/companies in the global osteoporosis drugs market?
Table of Contents
1 Preface3 Executive Summary10 Value Chain Analysis12 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Osteoporosis Drugs Market
6 Market Breakup by Product Type
7 Market Breakup by Route of Administration
8 Market Breakup by Region
9 SWOT Analysis
11 Porters Five Forces Analysis
13 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Amgen Inc.
- Eli Lilly
- Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Radius Health Inc.
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 141 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 16.6 Billion |
| Forecasted Market Value ( USD | $ 24.3 Billion |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
